| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| 100mg | |||
| Other Sizes |
| Targets |
HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, HDAC10, and HDAC11.
|
|---|---|
| ln Vitro |
Punctate nuclear staining of acetyl histone H3 shows that MC1742 (Compound 1) (0.5 and 2 μM; 24 h) enhances acetylation in a dose-dependent manner [1]. In all CSC cultures, MC1742 (0.5, 1 and 2 μM; 24, 48, and 72 hours) strongly triggered apoptosis [1]. A notable dose-dependent increase in bone nodule development is observed with MC1742 (0.025-0.5 μM; 14 days) [1]. The use of immunofluorescence
MC1742 shows potent HDAC inhibition with IC50 values: HDAC6 0.007 μM, HDAC3 0.02 μM, HDAC10 0.04 μM, HDAC1 0.1 μM, HDAC11 0.1 μM, HDAC2 0.11 μM, and HDAC8 0.61 μM. It increases acetylated H3 and acetylated tubulin levels in a dose-dependent manner (0.5 and 2 μM; 24 h). |
| ln Vivo |
MC1742 (0.5, 1, and 2 μM; 24, 48, and 72 h) significantly induces apoptosis in cancer stem cell cultures. It also promotes bone nodule formation in a dose-dependent manner (0.025-0.5 μM; 14 days). MC1742 inhibits the growth of Toxoplasma gondii tachyzoites in vitro.
|
| Enzyme Assay |
HDAC enzyme activity is measured using fluorogenic HDAC assay kits. Recombinant human HDAC isoforms are incubated with fluorogenic substrate (e.g., Ac-Lys(Ac)-AMC) and varying concentrations of MC1742. After deacetylation, the developer releases the fluorophore, and fluorescence is measured to determine IC50 values.
|
| Cell Assay |
Immunofluorescence
Cell Types: Sarcoma Stem Cells [1] Tested Concentrations: 0.5 and 2 μM Incubation Duration: 24 hrs (hours) Experimental Results: The degree of acetylation increased in a dose-dependent manner, as observed by punctate nuclear staining of acetyl histone H3. Apoptosis analysis Cell Types: Sarcoma Stem Cells [1] Tested Concentrations: 0.5, 1 and 2 μM Incubation Duration: 24, 48 and 72 hrs (hours) Experimental Results: Significant induction of apoptosis in all CSC cultures. Cell Differentiation Assay Cell Types: Sarcoma Stem Cells [1] Tested Concentrations: 0.025, 0.05, 0.1 and 0.5 μM Incubation Duration: 14 days Experimental Results: Successfully enhanced bone nodule formation in a significant dose-dependent manner. Cancer stem cells are cultured with MC1742 at concentrations of 0.5, 1, and 2 μM for 24, 48, and 72 h. Apoptosis is assessed by Annexin V/PI staining and flow cytometry. Acetylation levels of histone H3 and tubulin are evaluated by Western blot and immunofluorescence staining. |
| Animal Protocol |
In vivo animal studies for MC1742 are limited. As a broad-spectrum HDAC inhibitor, it would typically be evaluated in mouse xenograft models of cancer, administered via intraperitoneal or oral routes. Tumor growth inhibition, survival, and biomarker modulation (acetylated proteins) would be assessed.
|
| ADME/Pharmacokinetics |
MC1742 has molecular weight 395.48 and formula C21H21N3O3S. It is a solid compound with 99.20% purity. As a small-molecule HDAC inhibitor, it is suitable for both in vitro enzyme assays and cell-based studies. Detailed PK parameters are expected to be available in primary research publications.
|
| Toxicity/Toxicokinetics |
Preclinical toxicity data for MC1742 are limited. As a broad-spectrum HDAC inhibitor, potential toxicities may include effects on normal cell proliferation and differentiation. Standard toxicological assessments would be required for clinical development.
|
| References | |
| Additional Infomation |
MC1742 is a research compound with potential anticancer and antiparasitic activities. Its mechanism involves inhibition of HDAC enzymes, leading to increased histone and non-histone protein acetylation, which alters gene expression and induces cancer cell differentiation and apoptosis. No clinical trials or approved indications exist.
|
| Molecular Formula |
C21H21N3O3S
|
|---|---|
| Molecular Weight |
395.477
|
| Exact Mass |
395.13
|
| CAS # |
1776116-74-5
|
| PubChem CID |
136173089
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Index of Refraction |
1.649
|
| LogP |
3.24
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
28
|
| Complexity |
606
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C(C=C1)C2=CC=C(C=C2)C3=CC(=O)NC(=N3)SCCCCC(=O)NO
|
| InChi Key |
AOFVDNFTELWRHV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H21N3O3S/c25-19(24-27)8-4-5-13-28-21-22-18(14-20(26)23-21)17-11-9-16(10-12-17)15-6-2-1-3-7-15/h1-3,6-7,9-12,14,27H,4-5,8,13H2,(H,24,25)(H,22,23,26)
|
| Chemical Name |
N-hydroxy-5-[[6-oxo-4-(4-phenylphenyl)-1H-pyrimidin-2-yl]sulfanyl]pentanamide
|
| Synonyms |
MC1742; MC 1742; MC-1742
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~200 mg/mL (~505.73 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5286 mL | 12.6429 mL | 25.2857 mL | |
| 5 mM | 0.5057 mL | 2.5286 mL | 5.0571 mL | |
| 10 mM | 0.2529 mL | 1.2643 mL | 2.5286 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
